APO Research
Talk to an analyst

APO RESEARCH · REPORT

IL-23 Receptor Antagonist

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global IL-23 Receptor Antagonist Market Outlook and Growth Opportunities 2026

27 December 2025192 pages

Choose your research edition.

Industry ResearchIL-23 Receptor Antagonist Industry Research Report 2026135 pages · $2,950 USDIndustry Growth & TrendsGlobal IL-23 Receptor Antagonist Industry Growth and Trends Forecast to 2032117 pages · $3,450 USDMarket StructureGlobal IL-23 Receptor Antagonist Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal IL-23 Receptor Antagonist Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal IL-23 Receptor Antagonist Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global IL-23 Receptor Antagonist market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for IL-23 Receptor Antagonist is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for IL-23 Receptor Antagonist is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for IL-23 Receptor Antagonist is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the IL-23 Receptor Antagonist market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the IL-23 Receptor Antagonist market include Qyuns Therapeutics, China Medical System, Huadong Medicine, Bio-Thera Solutions, Teva, Sun Pharma, Sandoz, Samsung Bioepis and Janssen Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global IL-23 Receptor Antagonist market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of IL-23 Receptor Antagonist and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents IL-23 Receptor Antagonist sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the IL-23 Receptor Antagonist market size, projected growth trends, production technologies, key applications, and end-use industries.

IL-23 Receptor Antagonist Segment by Company

Qyuns Therapeutics

China Medical System

Huadong Medicine

Bio-Thera Solutions

Teva

Sun Pharma

Sandoz

Samsung Bioepis

Janssen Pharmaceuticals

Eli Lilly

Celltrion

Biocon Biologics

Amgen

Almirall

AbbVie Biotechnology

IL-23 Receptor Antagonist Segment by Type

Briakinumab

Guselkumab

Mirikizumab

Risankizumab

Tildrakizumab

Ustekinumab

Other

IL-23 Receptor Antagonist Segment by Application

Plaque Psoriasis

Crohn's Disease

Psoriatic Arthritis

Other

IL-23 Receptor Antagonist Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global IL-23 Receptor Antagonist status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions IL-23 Receptor Antagonist market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify IL-23 Receptor Antagonist significant trends, drivers, influence factors in global and regions.

6. To analyze IL-23 Receptor Antagonist competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global IL-23 Receptor Antagonist market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of IL-23 Receptor Antagonist and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of IL-23 Receptor Antagonist.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the IL-23 Receptor Antagonist market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global IL-23 Receptor Antagonist industry.

Chapter 3: Detailed analysis of IL-23 Receptor Antagonist manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of IL-23 Receptor Antagonist in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of IL-23 Receptor Antagonist in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. IL-23 Receptor Antagonist Industry Trends Table 2. IL-23 Receptor Antagonist Industry Drivers Table 3. IL-23 Receptor Antagonist Industry Opportunities and Challenges Table 4. IL-23 Receptor Antagonist Industry Restraints Table 5. Global IL-23 Receptor Antagonist Revenue by Company (US$ Million) & (2021-2026) Table 6. Global IL-23 Receptor Antagonist Revenue Share by Company (2021-2026) Table 7. Global IL-23 Receptor Antagonist Sales Volume by Company (K Units) & (2021-2026) Table 8. Global IL-23 Receptor Antagonist Sales Volume Share by Company (2021-2026) Table 9. Global IL-23 Receptor Antagonist Average Price (US$/Unit) of Company (2021-2026) Table 10. Global IL-23 Receptor Antagonist Company Ranking, (2024-2026) & (USD Million) Table 11. Global IL-23 Receptor Antagonist Key Company Manufacturing Base & Headquarters Table 12. Global IL-23 Receptor Antagonist Company, Product Type & Application Table 13. Global IL-23 Receptor Antagonist Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global IL-23 Receptor Antagonist by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Briakinumab Table 18. Significant Companies of Guselkumab Table 19. Significant Companies of Mirikizumab Table 20. Significant Companies of Risankizumab Table 21. Significant Companies of Tildrakizumab Table 22. Significant Companies of Ustekinumab Table 23. Significant Companies of Other Table 24. Global IL-23 Receptor Antagonist Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 25. Global IL-23 Receptor Antagonist Sales Volume by Type (2021-2026) & (K Units) Table 26. Global IL-23 Receptor Antagonist Sales Volume by Type (2027-2032) & (K Units) Table 27. Global IL-23 Receptor Antagonist Sales Volume Share by Type (2021-2026) Table 28. Global IL-23 Receptor Antagonist Sales Volume Share by Type (2027-2032) Table 29. Global IL-23 Receptor Antagonist Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global IL-23 Receptor Antagonist Sales Value by Type (2021-2026) & (US$ Million) Table 31. Global IL-23 Receptor Antagonist Sales Value by Type (2027-2032) & (US$ Million) Table 32. Global IL-23 Receptor Antagonist Sales Value Share by Type (2021-2026) Table 33. Global IL-23 Receptor Antagonist Sales Value Share by Type (2027-2032) Table 34. Significant Companies of Plaque Psoriasis Table 35. Significant Companies of Crohn's Disease Table 36. Significant Companies of Psoriatic Arthritis Table 37. Significant Companies of Other Table 38. Global IL-23 Receptor Antagonist Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 39. Global IL-23 Receptor Antagonist Sales Volume by Application (2021-2026) & (K Units) Table 40. Global IL-23 Receptor Antagonist Sales Volume by Application (2027-2032) & (K Units) Table 41. Global IL-23 Receptor Antagonist Sales Volume Share by Application (2021-2026) Table 42. Global IL-23 Receptor Antagonist Sales Volume Share by Application (2027-2032) Table 43. Global IL-23 Receptor Antagonist Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 44. Global IL-23 Receptor Antagonist Sales Value by Application (2021-2026) & (US$ Million) Table 45. Global IL-23 Receptor Antagonist Sales Value by Application (2027-2032) & (US$ Million) Table 46. Global IL-23 Receptor Antagonist Sales Value Share by Application (2021-2026) Table 47. Global IL-23 Receptor Antagonist Sales Value Share by Application (2027-2032) Table 48. Global IL-23 Receptor Antagonist Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 49. Global IL-23 Receptor Antagonist Sales by Region (2021-2026) & (K Units) Table 50. Global IL-23 Receptor Antagonist Sales Market Share by Region (2021-2026) Table 51. Global IL-23 Receptor Antagonist Sales by Region (2027-2032) & (K Units) Table 52. Global IL-23 Receptor Antagonist Sales Market Share by Region (2027-2032) Table 53. Global IL-23 Receptor Antagonist Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 54. Global IL-23 Receptor Antagonist Sales Value by Region (2021-2026) & (US$ Million) Table 55. Global IL-23 Receptor Antagonist Sales Value Share by Region (2021-2026) Table 56. Global IL-23 Receptor Antagonist Sales Value by Region (2027-2032) & (US$ Million) Table 57. Global IL-23 Receptor Antagonist Sales Value Share by Region (2027-2032) Table 58. Global IL-23 Receptor Antagonist Market Average Price (US$/Unit) by Region (2021-2026) Table 59. Global IL-23 Receptor Antagonist Market Average Price (US$/Unit) by Region (2027-2032) Table 60. Global IL-23 Receptor Antagonist Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 61. Global IL-23 Receptor Antagonist Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 62. Global IL-23 Receptor Antagonist Sales by Country (2021-2026) & (K Units) Table 63. Global IL-23 Receptor Antagonist Sales Market Share by Country (2021-2026) Table 64. Global IL-23 Receptor Antagonist Sales by Country (2027-2032) & (K Units) Table 65. Global IL-23 Receptor Antagonist Sales Market Share by Country (2027-2032) Table 66. Global IL-23 Receptor Antagonist Sales Value by Country (2021-2026) & (US$ Million) Table 67. Global IL-23 Receptor Antagonist Sales Value Market Share by Country (2021-2026) Table 68. Global IL-23 Receptor Antagonist Sales Value by Country (2027-2032) & (US$ Million) Table 69. Global IL-23 Receptor Antagonist Sales Value Market Share by Country (2027-2032) Table 70. Qyuns Therapeutics Company Information Table 71. Qyuns Therapeutics Business Overview Table 72. Qyuns Therapeutics IL-23 Receptor Antagonist Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 73. Qyuns Therapeutics IL-23 Receptor Antagonist Product Portfolio Table 74. Qyuns Therapeutics Recent Development Table 75. China Medical System Company Information Table 76. China Medical System Business Overview Table 77. China Medical System IL-23 Receptor Antagonist Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 78. China Medical System IL-23 Receptor Antagonist Product Portfolio Table 79. China Medical System Recent Development Table 80. Huadong Medicine Company Information Table 81. Huadong Medicine Business Overview Table 82. Huadong Medicine IL-23 Receptor Antagonist Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 83. Huadong Medicine IL-23 Receptor Antagonist Product Portfolio Table 84. Huadong Medicine Recent Development Table 85. Bio-Thera Solutions Company Information Table 86. Bio-Thera Solutions Business Overview Table 87. Bio-Thera Solutions IL-23 Receptor Antagonist Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 88. Bio-Thera Solutions IL-23 Receptor Antagonist Product Portfolio Table 89. Bio-Thera Solutions Recent Development Table 90. Teva Company Information Table 91. Teva Business Overview Table 92. Teva IL-23 Receptor Antagonist Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 93. Teva IL-23 Receptor Antagonist Product Portfolio Table 94. Teva Recent Development Table 95. Sun Pharma Company Information Table 96. Sun Pharma Business Overview Table 97. Sun Pharma IL-23 Receptor Antagonist Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 98. Sun Pharma IL-23 Receptor Antagonist Product Portfolio Table 99. Sun Pharma Recent Development Table 100. Sandoz Company Information Table 101. Sandoz Business Overview Table 102. Sandoz IL-23 Receptor Antagonist Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 103. Sandoz IL-23 Receptor Antagonist Product Portfolio Table 104. Sandoz Recent Development Table 105. Samsung Bioepis Company Information Table 106. Samsung Bioepis Business Overview Table 107. Samsung Bioepis IL-23 Receptor Antagonist Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 108. Samsung Bioepis IL-23 Receptor Antagonist Product Portfolio Table 109. Samsung Bioepis Recent Development Table 110. Janssen Pharmaceuticals Company Information Table 111. Janssen Pharmaceuticals Business Overview Table 112. Janssen Pharmaceuticals IL-23 Receptor Antagonist Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 113. Janssen Pharmaceuticals IL-23 Receptor Antagonist Product Portfolio Table 114. Janssen Pharmaceuticals Recent Development Table 115. Eli Lilly Company Information Table 116. Eli Lilly Business Overview Table 117. Eli Lilly IL-23 Receptor Antagonist Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 118. Eli Lilly IL-23 Receptor Antagonist Product Portfolio Table 119. Eli Lilly Recent Development Table 120. Celltrion Company Information Table 121. Celltrion Business Overview Table 122. Celltrion IL-23 Receptor Antagonist Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 123. Celltrion IL-23 Receptor Antagonist Product Portfolio Table 124. Celltrion Recent Development Table 125. Biocon Biologics Company Information Table 126. Biocon Biologics Business Overview Table 127. Biocon Biologics IL-23 Receptor Antagonist Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 128. Biocon Biologics IL-23 Receptor Antagonist Product Portfolio Table 129. Biocon Biologics Recent Development Table 130. Amgen Company Information Table 131. Amgen Business Overview Table 132. Amgen IL-23 Receptor Antagonist Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 133. Amgen IL-23 Receptor Antagonist Product Portfolio Table 134. Amgen Recent Development Table 135. Almirall Company Information Table 136. Almirall Business Overview Table 137. Almirall IL-23 Receptor Antagonist Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 138. Almirall IL-23 Receptor Antagonist Product Portfolio Table 139. Almirall Recent Development Table 140. AbbVie Biotechnology Company Information Table 141. AbbVie Biotechnology Business Overview Table 142. AbbVie Biotechnology IL-23 Receptor Antagonist Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 143. AbbVie Biotechnology IL-23 Receptor Antagonist Product Portfolio Table 144. AbbVie Biotechnology Recent Development Table 145. Key Raw Materials Table 146. Raw Materials Key Suppliers Table 147. IL-23 Receptor Antagonist Distributors List Table 148. IL-23 Receptor Antagonist Customers List Table 149. Research Programs/Design for This Report Table 150. Authors List of This Report Table 151. Secondary Sources Table 152. Primary Sources List of Figures Figure 1. IL-23 Receptor Antagonist Product Image Figure 2. Global IL-23 Receptor Antagonist Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global IL-23 Receptor Antagonist Sales Value (2021-2032) & (US$ Million) Figure 4. Global IL-23 Receptor Antagonist Sales (2021-2032) & (K Units) Figure 5. Global IL-23 Receptor Antagonist Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global IL-23 Receptor Antagonist Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Briakinumab Image Figure 10. Guselkumab Image Figure 11. Mirikizumab Image Figure 12. Risankizumab Image Figure 13. Tildrakizumab Image Figure 14. Ustekinumab Image Figure 15. Other Image Figure 16. Global IL-23 Receptor Antagonist Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 17. Global IL-23 Receptor Antagonist Sales Volume Share 2021 VS 2025 VS 2032 Figure 18. Global IL-23 Receptor Antagonist Sales Volume Share by Type (2021-2032) Figure 19. Global IL-23 Receptor Antagonist Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global IL-23 Receptor Antagonist Sales Value Share 2021 VS 2025 VS 2032 Figure 21. Global IL-23 Receptor Antagonist Sales Value Share by Type (2021-2032) Figure 22. Plaque Psoriasis Image Figure 23. Crohn's Disease Image Figure 24. Psoriatic Arthritis Image Figure 25. Other Image Figure 26. Global IL-23 Receptor Antagonist Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 27. Global IL-23 Receptor Antagonist Sales Volume Share 2021 VS 2025 VS 2032 Figure 28. Global IL-23 Receptor Antagonist Sales Volume Share by Application (2021-2032) Figure 29. Global IL-23 Receptor Antagonist Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 30. Global IL-23 Receptor Antagonist Sales Value Share 2021 VS 2025 VS 2032 Figure 31. Global IL-23 Receptor Antagonist Sales Value Share by Application (2021-2032) Figure 32. Global IL-23 Receptor Antagonist Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 33. Global IL-23 Receptor Antagonist Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 34. Global IL-23 Receptor Antagonist Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 35. Global IL-23 Receptor Antagonist Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 36. North America IL-23 Receptor Antagonist Sales Value (2021-2032) & (US$ Million) Figure 37. North America IL-23 Receptor Antagonist Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Europe IL-23 Receptor Antagonist Sales Value (2021-2032) & (US$ Million) Figure 39. Europe IL-23 Receptor Antagonist Sales Value Share by Country (%), 2025 VS 2032 Figure 40. Asia-Pacific IL-23 Receptor Antagonist Sales Value (2021-2032) & (US$ Million) Figure 41. Asia-Pacific IL-23 Receptor Antagonist Sales Value Share by Country (%), 2025 VS 2032 Figure 42. South America IL-23 Receptor Antagonist Sales Value (2021-2032) & (US$ Million) Figure 43. South America IL-23 Receptor Antagonist Sales Value Share by Country (%), 2025 VS 2032 Figure 44. Middle East & Africa IL-23 Receptor Antagonist Sales Value (2021-2032) & (US$ Million) Figure 45. Middle East & Africa IL-23 Receptor Antagonist Sales Value Share by Country (%), 2025 VS 2032 Figure 46. USA IL-23 Receptor Antagonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. USA IL-23 Receptor Antagonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. USA IL-23 Receptor Antagonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Canada IL-23 Receptor Antagonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Canada IL-23 Receptor Antagonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Canada IL-23 Receptor Antagonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Mexico IL-23 Receptor Antagonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Mexico IL-23 Receptor Antagonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Mexico IL-23 Receptor Antagonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Germany IL-23 Receptor Antagonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Germany IL-23 Receptor Antagonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Germany IL-23 Receptor Antagonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. France IL-23 Receptor Antagonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. France IL-23 Receptor Antagonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. France IL-23 Receptor Antagonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. U.K. IL-23 Receptor Antagonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. U.K. IL-23 Receptor Antagonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. U.K. IL-23 Receptor Antagonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Italy IL-23 Receptor Antagonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Italy IL-23 Receptor Antagonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Italy IL-23 Receptor Antagonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Spain IL-23 Receptor Antagonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Spain IL-23 Receptor Antagonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Spain IL-23 Receptor Antagonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Russia IL-23 Receptor Antagonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Russia IL-23 Receptor Antagonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Russia IL-23 Receptor Antagonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. Netherlands IL-23 Receptor Antagonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. Netherlands IL-23 Receptor Antagonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. Netherlands IL-23 Receptor Antagonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Nordic Countries IL-23 Receptor Antagonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Nordic Countries IL-23 Receptor Antagonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Nordic Countries IL-23 Receptor Antagonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. China IL-23 Receptor Antagonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. China IL-23 Receptor Antagonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. China IL-23 Receptor Antagonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Japan IL-23 Receptor Antagonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Japan IL-23 Receptor Antagonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Japan IL-23 Receptor Antagonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. South Korea IL-23 Receptor Antagonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. South Korea IL-23 Receptor Antagonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. South Korea IL-23 Receptor Antagonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. India IL-23 Receptor Antagonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. India IL-23 Receptor Antagonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. India IL-23 Receptor Antagonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Australia IL-23 Receptor Antagonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Australia IL-23 Receptor Antagonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Australia IL-23 Receptor Antagonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Southeast Asia IL-23 Receptor Antagonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Southeast Asia IL-23 Receptor Antagonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Southeast Asia IL-23 Receptor Antagonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Brazil IL-23 Receptor Antagonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Brazil IL-23 Receptor Antagonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Brazil IL-23 Receptor Antagonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Argentina IL-23 Receptor Antagonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Argentina IL-23 Receptor Antagonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Argentina IL-23 Receptor Antagonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Chile IL-23 Receptor Antagonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Chile IL-23 Receptor Antagonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Chile IL-23 Receptor Antagonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Colombia IL-23 Receptor Antagonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Colombia IL-23 Receptor Antagonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Colombia IL-23 Receptor Antagonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Peru IL-23 Receptor Antagonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Peru IL-23 Receptor Antagonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Peru IL-23 Receptor Antagonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Saudi Arabia IL-23 Receptor Antagonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Saudi Arabia IL-23 Receptor Antagonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Saudi Arabia IL-23 Receptor Antagonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Israel IL-23 Receptor Antagonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Israel Arabia IL-23 Receptor Antagonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Israel Arabia IL-23 Receptor Antagonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. UAE IL-23 Receptor Antagonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. UAE IL-23 Receptor Antagonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. UAE IL-23 Receptor Antagonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Turkey IL-23 Receptor Antagonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Turkey IL-23 Receptor Antagonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Turkey IL-23 Receptor Antagonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Iran IL-23 Receptor Antagonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 125. Iran IL-23 Receptor Antagonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 126. Iran IL-23 Receptor Antagonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 127. Egypt IL-23 Receptor Antagonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 128. Egypt IL-23 Receptor Antagonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 129. Egypt IL-23 Receptor Antagonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 130. IL-23 Receptor Antagonist Value Chain Figure 131. Manufacturing Cost Structure Figure 132. IL-23 Receptor Antagonist Sales Mode & Process Figure 133. Direct Comparison with Distribution Share Figure 134. Distributors Profiles Figure 135. Years Considered Figure 136. Research Process Figure 137. Key Executives Interviewed

Scope & coverage.

Types
  • Briakinumab
  • Guselkumab
  • Mirikizumab
  • Risankizumab
  • Tildrakizumab
  • Ustekinumab
  • Other
Applications
  • Plaque Psoriasis
  • Crohn's Disease
  • Psoriatic Arthritis
  • Other
Companies covered
  • Qyuns Therapeutics
  • China Medical System
  • Huadong Medicine
  • Bio-Thera Solutions
  • Teva
  • Sun Pharma
  • Sandoz
  • Samsung Bioepis
  • Janssen Pharmaceuticals
  • Eli Lilly
  • Celltrion
  • Biocon Biologics
  • Amgen
  • Almirall
  • AbbVie Biotechnology

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global IL-23 Receptor Antagonist Sales Value (2021-2032)
  4. 1.2.2 Global IL-23 Receptor Antagonist Sales Volume (2021-2032)
  5. 1.2.3 Global IL-23 Receptor Antagonist Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 IL-23 Receptor Antagonist Market Dynamics
  1. 2.1 IL-23 Receptor Antagonist Industry Trends
  2. 2.2 IL-23 Receptor Antagonist Industry Drivers
  3. 2.3 IL-23 Receptor Antagonist Industry Opportunities and Challenges
  4. 2.4 IL-23 Receptor Antagonist Industry Restraints
3 IL-23 Receptor Antagonist Market by Company
  1. 3.1 Global IL-23 Receptor Antagonist Company Revenue Ranking in 2025
  2. 3.2 Global IL-23 Receptor Antagonist Revenue by Company (2021-2026)
  3. 3.3 Global IL-23 Receptor Antagonist Sales Volume by Company (2021-2026)
  4. 3.4 Global IL-23 Receptor Antagonist Average Price by Company (2021-2026)
  5. 3.5 Global IL-23 Receptor Antagonist Company Ranking (2024-2026)
  6. 3.6 Global IL-23 Receptor Antagonist Company Manufacturing Base and Headquarters
  7. 3.7 Global IL-23 Receptor Antagonist Company Product Type and Application
  8. 3.8 Global IL-23 Receptor Antagonist Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global IL-23 Receptor Antagonist Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 IL-23 Receptor Antagonist Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 IL-23 Receptor Antagonist Market by Type
  1. 4.1 IL-23 Receptor Antagonist Type Introduction
  2. 4.1.1 Briakinumab
  3. 4.1.2 Guselkumab
  4. 4.1.3 Mirikizumab
  5. 4.1.4 Risankizumab
  6. 4.1.5 Tildrakizumab
  7. 4.1.6 Ustekinumab
  8. 4.1.7 Other
  9. 4.2 Global IL-23 Receptor Antagonist Sales Volume by Type
  10. 4.2.1 Global IL-23 Receptor Antagonist Sales Volume by Type (2021 VS 2025 VS 2032)
  11. 4.2.2 Global IL-23 Receptor Antagonist Sales Volume by Type (2021-2032)
  12. 4.2.3 Global IL-23 Receptor Antagonist Sales Volume Share by Type (2021-2032)
  13. 4.3 Global IL-23 Receptor Antagonist Sales Value by Type
  14. 4.3.1 Global IL-23 Receptor Antagonist Sales Value by Type (2021 VS 2025 VS 2032)
  15. 4.3.2 Global IL-23 Receptor Antagonist Sales Value by Type (2021-2032)
  16. 4.3.3 Global IL-23 Receptor Antagonist Sales Value Share by Type (2021-2032)
5 IL-23 Receptor Antagonist Market by Application
  1. 5.1 IL-23 Receptor Antagonist Application Introduction
  2. 5.1.1 Plaque Psoriasis
  3. 5.1.2 Crohn's Disease
  4. 5.1.3 Psoriatic Arthritis
  5. 5.1.4 Other
  6. 5.2 Global IL-23 Receptor Antagonist Sales Volume by Application
  7. 5.2.1 Global IL-23 Receptor Antagonist Sales Volume by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global IL-23 Receptor Antagonist Sales Volume by Application (2021-2032)
  9. 5.2.3 Global IL-23 Receptor Antagonist Sales Volume Share by Application (2021-2032)
  10. 5.3 Global IL-23 Receptor Antagonist Sales Value by Application
  11. 5.3.1 Global IL-23 Receptor Antagonist Sales Value by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global IL-23 Receptor Antagonist Sales Value by Application (2021-2032)
  13. 5.3.3 Global IL-23 Receptor Antagonist Sales Value Share by Application (2021-2032)
6 IL-23 Receptor Antagonist Regional Sales and Value Analysis
  1. 6.1 Global IL-23 Receptor Antagonist Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global IL-23 Receptor Antagonist Sales by Region (2021-2032)
  3. 6.2.1 Global IL-23 Receptor Antagonist Sales by Region: 2021-2026
  4. 6.2.2 Global IL-23 Receptor Antagonist Sales by Region (2027-2032)
  5. 6.3 Global IL-23 Receptor Antagonist Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global IL-23 Receptor Antagonist Sales Value by Region (2021-2032)
  7. 6.4.1 Global IL-23 Receptor Antagonist Sales Value by Region: 2021-2026
  8. 6.4.2 Global IL-23 Receptor Antagonist Sales Value by Region (2027-2032)
  9. 6.5 Global IL-23 Receptor Antagonist Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America IL-23 Receptor Antagonist Sales Value (2021-2032)
  12. 6.6.2 North America IL-23 Receptor Antagonist Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe IL-23 Receptor Antagonist Sales Value (2021-2032)
  15. 6.7.2 Europe IL-23 Receptor Antagonist Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific IL-23 Receptor Antagonist Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific IL-23 Receptor Antagonist Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America IL-23 Receptor Antagonist Sales Value (2021-2032)
  21. 6.9.2 South America IL-23 Receptor Antagonist Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa IL-23 Receptor Antagonist Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa IL-23 Receptor Antagonist Sales Value Share by Country, 2025 VS 2032
7 IL-23 Receptor Antagonist Country-level Sales and Value Analysis
  1. 7.1 Global IL-23 Receptor Antagonist Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global IL-23 Receptor Antagonist Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global IL-23 Receptor Antagonist Sales by Country (2021-2032)
  4. 7.3.1 Global IL-23 Receptor Antagonist Sales by Country (2021-2026)
  5. 7.3.2 Global IL-23 Receptor Antagonist Sales by Country (2027-2032)
  6. 7.4 Global IL-23 Receptor Antagonist Sales Value by Country (2021-2032)
  7. 7.4.1 Global IL-23 Receptor Antagonist Sales Value by Country (2021-2026)
  8. 7.4.2 Global IL-23 Receptor Antagonist Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA IL-23 Receptor Antagonist Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA IL-23 Receptor Antagonist Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA IL-23 Receptor Antagonist Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada IL-23 Receptor Antagonist Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada IL-23 Receptor Antagonist Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada IL-23 Receptor Antagonist Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico IL-23 Receptor Antagonist Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico IL-23 Receptor Antagonist Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico IL-23 Receptor Antagonist Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany IL-23 Receptor Antagonist Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany IL-23 Receptor Antagonist Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany IL-23 Receptor Antagonist Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France IL-23 Receptor Antagonist Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France IL-23 Receptor Antagonist Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France IL-23 Receptor Antagonist Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. IL-23 Receptor Antagonist Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. IL-23 Receptor Antagonist Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. IL-23 Receptor Antagonist Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy IL-23 Receptor Antagonist Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy IL-23 Receptor Antagonist Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy IL-23 Receptor Antagonist Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain IL-23 Receptor Antagonist Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain IL-23 Receptor Antagonist Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain IL-23 Receptor Antagonist Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia IL-23 Receptor Antagonist Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia IL-23 Receptor Antagonist Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia IL-23 Receptor Antagonist Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands IL-23 Receptor Antagonist Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands IL-23 Receptor Antagonist Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands IL-23 Receptor Antagonist Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries IL-23 Receptor Antagonist Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries IL-23 Receptor Antagonist Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries IL-23 Receptor Antagonist Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China IL-23 Receptor Antagonist Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China IL-23 Receptor Antagonist Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China IL-23 Receptor Antagonist Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan IL-23 Receptor Antagonist Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan IL-23 Receptor Antagonist Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan IL-23 Receptor Antagonist Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea IL-23 Receptor Antagonist Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea IL-23 Receptor Antagonist Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea IL-23 Receptor Antagonist Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India IL-23 Receptor Antagonist Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India IL-23 Receptor Antagonist Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India IL-23 Receptor Antagonist Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia IL-23 Receptor Antagonist Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia IL-23 Receptor Antagonist Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia IL-23 Receptor Antagonist Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia IL-23 Receptor Antagonist Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia IL-23 Receptor Antagonist Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia IL-23 Receptor Antagonist Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil IL-23 Receptor Antagonist Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil IL-23 Receptor Antagonist Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil IL-23 Receptor Antagonist Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina IL-23 Receptor Antagonist Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina IL-23 Receptor Antagonist Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina IL-23 Receptor Antagonist Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile IL-23 Receptor Antagonist Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile IL-23 Receptor Antagonist Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile IL-23 Receptor Antagonist Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia IL-23 Receptor Antagonist Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia IL-23 Receptor Antagonist Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia IL-23 Receptor Antagonist Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru IL-23 Receptor Antagonist Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru IL-23 Receptor Antagonist Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru IL-23 Receptor Antagonist Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia IL-23 Receptor Antagonist Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia IL-23 Receptor Antagonist Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia IL-23 Receptor Antagonist Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel IL-23 Receptor Antagonist Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel IL-23 Receptor Antagonist Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel IL-23 Receptor Antagonist Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE IL-23 Receptor Antagonist Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE IL-23 Receptor Antagonist Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE IL-23 Receptor Antagonist Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey IL-23 Receptor Antagonist Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey IL-23 Receptor Antagonist Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey IL-23 Receptor Antagonist Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran IL-23 Receptor Antagonist Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran IL-23 Receptor Antagonist Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran IL-23 Receptor Antagonist Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt IL-23 Receptor Antagonist Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt IL-23 Receptor Antagonist Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt IL-23 Receptor Antagonist Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Qyuns Therapeutics
  2. 8.1.1 Qyuns Therapeutics Company Information
  3. 8.1.2 Qyuns Therapeutics Business Overview
  4. 8.1.3 Qyuns Therapeutics IL-23 Receptor Antagonist Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Qyuns Therapeutics IL-23 Receptor Antagonist Product Portfolio
  6. 8.1.5 Qyuns Therapeutics Recent Developments
  7. 8.2 China Medical System
  8. 8.2.1 China Medical System Company Information
  9. 8.2.2 China Medical System Business Overview
  10. 8.2.3 China Medical System IL-23 Receptor Antagonist Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 China Medical System IL-23 Receptor Antagonist Product Portfolio
  12. 8.2.5 China Medical System Recent Developments
  13. 8.3 Huadong Medicine
  14. 8.3.1 Huadong Medicine Company Information
  15. 8.3.2 Huadong Medicine Business Overview
  16. 8.3.3 Huadong Medicine IL-23 Receptor Antagonist Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Huadong Medicine IL-23 Receptor Antagonist Product Portfolio
  18. 8.3.5 Huadong Medicine Recent Developments
  19. 8.4 Bio-Thera Solutions
  20. 8.4.1 Bio-Thera Solutions Company Information
  21. 8.4.2 Bio-Thera Solutions Business Overview
  22. 8.4.3 Bio-Thera Solutions IL-23 Receptor Antagonist Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Bio-Thera Solutions IL-23 Receptor Antagonist Product Portfolio
  24. 8.4.5 Bio-Thera Solutions Recent Developments
  25. 8.5 Teva
  26. 8.5.1 Teva Company Information
  27. 8.5.2 Teva Business Overview
  28. 8.5.3 Teva IL-23 Receptor Antagonist Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Teva IL-23 Receptor Antagonist Product Portfolio
  30. 8.5.5 Teva Recent Developments
  31. 8.6 Sun Pharma
  32. 8.6.1 Sun Pharma Company Information
  33. 8.6.2 Sun Pharma Business Overview
  34. 8.6.3 Sun Pharma IL-23 Receptor Antagonist Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Sun Pharma IL-23 Receptor Antagonist Product Portfolio
  36. 8.6.5 Sun Pharma Recent Developments
  37. 8.7 Sandoz
  38. 8.7.1 Sandoz Company Information
  39. 8.7.2 Sandoz Business Overview
  40. 8.7.3 Sandoz IL-23 Receptor Antagonist Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Sandoz IL-23 Receptor Antagonist Product Portfolio
  42. 8.7.5 Sandoz Recent Developments
  43. 8.8 Samsung Bioepis
  44. 8.8.1 Samsung Bioepis Company Information
  45. 8.8.2 Samsung Bioepis Business Overview
  46. 8.8.3 Samsung Bioepis IL-23 Receptor Antagonist Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Samsung Bioepis IL-23 Receptor Antagonist Product Portfolio
  48. 8.8.5 Samsung Bioepis Recent Developments
  49. 8.9 Janssen Pharmaceuticals
  50. 8.9.1 Janssen Pharmaceuticals Company Information
  51. 8.9.2 Janssen Pharmaceuticals Business Overview
  52. 8.9.3 Janssen Pharmaceuticals IL-23 Receptor Antagonist Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Janssen Pharmaceuticals IL-23 Receptor Antagonist Product Portfolio
  54. 8.9.5 Janssen Pharmaceuticals Recent Developments
  55. 8.10 Eli Lilly
  56. 8.10.1 Eli Lilly Company Information
  57. 8.10.2 Eli Lilly Business Overview
  58. 8.10.3 Eli Lilly IL-23 Receptor Antagonist Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Eli Lilly IL-23 Receptor Antagonist Product Portfolio
  60. 8.10.5 Eli Lilly Recent Developments
  61. 8.11 Celltrion
  62. 8.11.1 Celltrion Company Information
  63. 8.11.2 Celltrion Business Overview
  64. 8.11.3 Celltrion IL-23 Receptor Antagonist Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Celltrion IL-23 Receptor Antagonist Product Portfolio
  66. 8.11.5 Celltrion Recent Developments
  67. 8.12 Biocon Biologics
  68. 8.12.1 Biocon Biologics Company Information
  69. 8.12.2 Biocon Biologics Business Overview
  70. 8.12.3 Biocon Biologics IL-23 Receptor Antagonist Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Biocon Biologics IL-23 Receptor Antagonist Product Portfolio
  72. 8.12.5 Biocon Biologics Recent Developments
  73. 8.13 Amgen
  74. 8.13.1 Amgen Company Information
  75. 8.13.2 Amgen Business Overview
  76. 8.13.3 Amgen IL-23 Receptor Antagonist Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Amgen IL-23 Receptor Antagonist Product Portfolio
  78. 8.13.5 Amgen Recent Developments
  79. 8.14 Almirall
  80. 8.14.1 Almirall Company Information
  81. 8.14.2 Almirall Business Overview
  82. 8.14.3 Almirall IL-23 Receptor Antagonist Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Almirall IL-23 Receptor Antagonist Product Portfolio
  84. 8.14.5 Almirall Recent Developments
  85. 8.15 AbbVie Biotechnology
  86. 8.15.1 AbbVie Biotechnology Company Information
  87. 8.15.2 AbbVie Biotechnology Business Overview
  88. 8.15.3 AbbVie Biotechnology IL-23 Receptor Antagonist Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 AbbVie Biotechnology IL-23 Receptor Antagonist Product Portfolio
  90. 8.15.5 AbbVie Biotechnology Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 IL-23 Receptor Antagonist Value Chain Analysis
  2. 9.1.1 IL-23 Receptor Antagonist Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 IL-23 Receptor Antagonist Sales Mode & Process
  6. 9.2 IL-23 Receptor Antagonist Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 IL-23 Receptor Antagonist Distributors
  9. 9.2.3 IL-23 Receptor Antagonist Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst